This trial is completed!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Metastatic Pancreatic Cancer
and you are
between 18 and 70
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The purpose of this study is to determine the response rate of gemcitabine, cisplatin and erlotinib in metastatic pancreatic cancer.

Provided treatments

  • Drug: Gemcitabine, Cisplatin, Erlotinib (Tarceva)
Tris trial is registered with FDA with number: NCT00922896. The sponsor of the trial is Gyeongsang National University Hospital and it is looking for 22 volunteers for the current phase.
Official trial title:
A Phase II Trial of Erlotinib in Combination With Gemcitabine and Cisplatin in Metastatic Pancreatic Cancer